Stock 1228 CANBRIDGE PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News CANbridge Pharmaceuticals Inc.

Equities

1228

KYG1821D1097

Market Closed - Hong Kong S.E.
Other stock markets
 09:08:22 10/05/2024 BST 		5-day change 1st Jan Change
0.34 HKD -4.23% Intraday chart for CANbridge Pharmaceuticals Inc. -25.27% -65.66%
04-23 Canbridge Pharmaceuticals Shelves Glioblastoma Drug After Phase II Clinical Trials MT
04-22 CANbridge Pharmaceuticals Inc. Announces Results of CAN008 Phase II Clinical Trial for the Treatment of Glioblastoma Multiforme CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Canbridge Pharmaceuticals Shelves Glioblastoma Drug After Phase II Clinical Trials
MT
CANbridge Pharmaceuticals Inc. Announces Results of CAN008 Phase II Clinical Trial for the Treatment of Glioblastoma Multiforme
CI
CANbridge Pharmaceuticals Inc. Announces Change of Principal Place of Business in Hong Kong, Effect from April 15, 2024
CI
CANbridge Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
CANbridge and PUMCH announced the establishment of PUMCH, CANbridge Genetic Defect Rare Disease Innovation and Translation Base
AQ
CANbridge Pharmaceuticals Grants Share Options, Restricted Shares
MT
CANbridge Pharmaceuticals Inc. Announces Resignation of Derek Paul Di Rocco as Non-Executive Director and A Member of the Nomination and Corporate Governance Committee
CI
CANbridge Pharmaceuticals - Foundation consolidated over time and for a rosy future, 2023 China Conference on Rare Diseases closed successfully
AQ
CANbridge Pharmaceuticals to Present Fabry Disease Gene Therapy Abstract at ESGCT 30th Annual Congress
AQ
CANbridge Pharmaceuticals Inc. to Present Fabry Disease Gene Therapy Abstract At Esgct 30Th Annual Congress
CI
CANbridge Announces NDA Acceptance of CAN108 for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis by China's National Medical Products Administration
AQ
CANbridge Announces NDA Acceptance of CAN108 (®/LIVMARLI®) for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis by China's National Medical Products Administration
CI
CANbridge Announces Full Enrollment Reached in the Core Part of the CAN103 Phase 2 trial for Gaucher Disease in China
AQ
Canbridge Pharmaceuticals Inc. Announces Full Enrollment Reached in the Core Part of the Can103 Phase 2 Trial for Gaucher Disease in China
CI
CANbridge Announces Marketing Approval of CAN108 in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
AQ
Canbridge Pharmaceuticals Inc. Announces Marketing Approval of Can108 (Maralixibat Chloride Oral Solution /Livmarli®?) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
CI
CANbridge to Participate in Two Investor Conferences in September
AQ
CANbridge Pharmaceuticals' H1 Attributable Loss Narrows
MT
CANbridge Pharmaceuticals Inc. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Transcript : CANbridge Pharmaceuticals Inc. - Special Call
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 1228 Stock
  4. News CANbridge Pharmaceuticals Inc.